Erucamide is a primary fatty amide resulting from the formal condensation of the carboxy group of erucic acid with ammonia.
定義
Erucamide is a primary fatty amide resulting from the formal condensation of the carboxy group of erucic acid with ammonia. It is commonly used as a slip additive in the plastic manufacturing industry. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a mammalian metabolite, a plant metabolite, a human metabolite and a rat metabolite. It is functionally related to an erucic acid.
出典: PubChem
米国FDA 物質登録 · UNII 0V89VY25BN · 登録名 ERUCAMIDE · 単一の化学物質
化粧品での役割
安全性・規制情報
韓国の有害物質GHS分類なし · 既存化学物質
詳しい資料 — 表示名・識別番号・物性・試験記録・文献
別名・識別情報
- CAS No.化学物質登録番号
- 3061-72-1
- CAS No.化学物質登録番号
- 112-84-5
- EC No.EU化学物質目録番号
- 931-599-5
- EC No.EU化学物質目録番号
- 204-009-2
- DTXSID米国EPA化学物質番号
- DTXSID4026929
- DTXCID米国EPA化合物番号
- DTXCID606929
- IUPAC
- (13Z)-Docos-13-enamide
- 分子式
- C22H43NO
- 分子量
- 337.592 g/mol
測定された物性
- 性状
- Dry Powder, Large Crystals, Other Solid, CBI · Solid, [Hawley] Off-white beads with a fatty odor, [MSDSonline]
- 融点
- 75-80 °C
- 溶解性
- SOL IN ISOPROPANOL, SLIGHTLY SOL IN ALCOHOL, ACETONE
- 融点・凝固点
- 77.5 ℃
- 初留点および沸点範囲
- 460~488 ℃
- 引火点
- 221~261 ℃ (計算値)
- 蒸気圧
- 0.00000000582 ㎜Hg (@ 25 ℃, 推定値)
- 溶解度
- 0.2 ㎎/ℓ (@ 25 ℃, 推定値)
- 蒸気密度
- 11.65
- 比重
- 0.908 (@ 20 ℃)
- n-オクタノール/水分配係数（Kow）
- 5.3 (推定値)
- 分子量
- 337.56
物質そのものを測定した値です。安全保健公団（KOSHA）の資料はSDS作成・確認の参考用で、原料商品の規格ではありません。
出典: PubChem · 韓国安全保健公団 SDS
製品が実際に使っている用途
米国EPAにこの成分を届け出た製品38件の用途です。化粧品以外の製品も含まれるため、上の数行がこの成分の主な使い道といえます。
- Anti-adhesive/cohesive19
- Lubricating agent7
- Processing aids not otherwise specified3
- Anti-slip agent3
- Hardener2
- Anti-static agent1
- Wetting agent (non-aqueous)1
- Opacifer1
その他の用途 1件
- Viscosity modifier1
出典: 米国EPA CompTox
刺激・感作試験の記録
皮膚試験4件・眼試験2件の記録があります。
試験の結論はおおむね一致しています（100%）。 原料そのものを試験した記録で、完成品に含まれる濃度での刺激性とは異なります。
試験6件をすべて見る
- Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) (2002) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay) (2008) - Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (1984) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (1984) according to
出典: 米国EPA CompTox
関連文献
- The ethyl acetate extract from Trichoderma viride fermentation acts by downregulating the leukocyte transendothelial migration signaling pathway to induce ferroptosis in triple-negative breast cancer cells · 2026
- Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor. · 2024
- Lipid Profiling of Oily Skin in Chinese Female aged 22-28 and 29-35 Defined by the Life Rhythm Theory of Huangdi Neijing · 2024
- Enhanced ready biodegradability screening tests for the evaluation of potential PBT substances. · 2022
- Identification of Phenolic Dermal Sensitizers in a Wound Closure Tape · 2007